Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
52.22
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Cathie Wood Has 37% of Her Ark Invest Portfolio Invested in These 7 Stocks
February 12, 2024
The famous investor owns some huge winners -- and big losers, too.
Via
The Motley Fool
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
February 11, 2024
Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector.
Via
InvestorPlace
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
February 09, 2024
Via
Benzinga
3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List
February 09, 2024
These strong buy healthcare stocks are among analysts' favorite picks, and their strong market position tells us why.
Via
InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
February 08, 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.
Via
InvestorPlace
Got $100? 2 Top Cathie Wood Stocks to Buy and Hold.
February 04, 2024
These stocks are steals right now.
Via
The Motley Fool
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
January 22, 2024
Via
Benzinga
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
January 22, 2024
CRISPR Therapeutics shares have soared 39% over the past three months.
Via
The Motley Fool
2 Healthcare Stocks to Buy Hand Over Fist in February
February 08, 2024
Both companies are proven innovators.
Via
The Motley Fool
Cathie Wood Just Bought These 3 Biotech Stocks. Should You?
February 07, 2024
They aren't all long shots, but they're all innovative.
Via
The Motley Fool
2 Cathie Wood Stocks I Plan on Buying for My Kids' Portfolios
February 05, 2024
These two Cathie Wood holdings are great long-term buys.
Via
The Motley Fool
Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements
February 01, 2024
Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio.
Via
InvestorPlace
Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock
January 31, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is taking a "hard pass" on Surgery Partners, Inc. (NASDAQ: SGRY). "That industry has been up and down and up and down," he added.
Via
Benzinga
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
January 30, 2024
Bull markets generally favor growth stocks, so now is a great time to buy quality growth players.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Is CRISPR Therapeutics a Buy in the New Bull Market?
January 30, 2024
CRISPR Therapeutics is a specialist in the hot technology of gene editing.
Via
The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week
January 28, 2024
Wood added to her existing positions in these three exciting companies.
Via
The Motley Fool
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
January 25, 2024
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.
Via
InvestorPlace
These 5 growth stocks are now in buy ranges
January 25, 2024
Affirm, MongoDB, UIPath, Synopsys and Crispr's charts signal buy opportunities as these top-performing tech and biotech stocks consolidate below prior highs.
Via
MarketBeat
Topics
ETFs
Where Will CRISPR Therapeutics Be in 5 Years?
January 24, 2024
The company could maintain the momentum it gained last year.
Via
The Motley Fool
1 Setback and 1 Opportunity for CRISPR Therapeutics Stock
January 23, 2024
Despite A bump in the road, the biotech's future looks sunny.
Via
The Motley Fool
2 gene editing stocks to keep on your 2024 watchlist
January 23, 2024
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)
Via
MarketBeat
Exposures
Product Safety
If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today
January 22, 2024
Has investing in Vertex been a better option than just putting your money in the S&P 500?
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks
January 22, 2024
The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase.
Via
Investor's Business Daily
Topics
ETFs
Could Editas Medicine Become the Next CRISPR Therapeutics?
January 21, 2024
The similarities between the pair are striking, but it might not be enough.
Via
The Motley Fool
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
January 21, 2024
Both companies are going to continue doing high-impact science in 2024.
Via
The Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
January 20, 2024
These big winners could keep the momentum going.
Via
The Motley Fool
3 Under-the-Radar Tech Stocks With 250% Growth Potential by 2026
January 18, 2024
Discover the trailblazing strategies of three tech stocks that are reshaping industries through innovation, adaptability and revenue surges.
Via
InvestorPlace
Cathie Wood's Ark Invest Sells $8.04M Worth of DraftKings Shares
January 17, 2024
Via
Benzinga
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
January 17, 2024
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the...
Via
Benzinga
Exposures
Product Safety
Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units
January 16, 2024
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units.
Via
Benzinga
Topics
ETFs
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.